Mallinckrodt presents clinical data for terlivaz® (terlipressin) for injection in adults with hepatorenal syndrome (hrs) at the american transplant congress (atc) 2023

– findings from two clinical studies in adults with hrs involving rapid reduction in kidney function1 provide insight into the use of terlipressin among patients with comorbidities and varying baseline characteristics2,3 – dublin , june 1, 2023 /prnewswire/ --  mallinckrodt plc (nyse american: mnk), a global specialty pharmaceutical company, today announced the presentation of results from two clinical studies in adults with hepatorenal syndrome (hrs) with rapid reduction in kidney function1 treated with terlivaz® (terlipressin) for injection at the american transplant congress (atc) 2023, taking place in san diego, calif. from june 3-7, 2023.
MNK Ratings Summary
MNK Quant Ranking